Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs.
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.25|
|52 Week High||CA$0.14|
|52 Week Low||CA$0.53|
|1 Month Change||-18.03%|
|3 Month Change||-27.54%|
|1 Year Change||72.41%|
|3 Year Change||-78.99%|
|5 Year Change||11.11%|
|Change since IPO||900.00%|
Recent News & Updates
Does Tetra Bio-Pharma (TSE:TBP) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|TBP||CA Pharmaceuticals||CA Market|
Return vs Industry: TBP exceeded the Canadian Pharmaceuticals industry which returned 39.6% over the past year.
Return vs Market: TBP exceeded the Canadian Market which returned 30.8% over the past year.
Stable Share Price: TBP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TBP's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. It develops ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; Reduvo for chemotherapy-induced nausea and vomiting; PLENITUDE to treat advanced uncontrolled cancer pain; REBORN for the treatment of breakthrough cancer pain and fibromyalgia; and SERENITY to treat cancer cachexia. The company also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Fundamentals Summary
|TBP fundamental statistics|
Is TBP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TBP income statement (TTM)|
|Cost of Revenue||CA$0|
Last Reported Earnings
May 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.071|
|Net Profit Margin||0.00%|
How did TBP perform over the long term?See historical performance and comparison
Is Tetra Bio-Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TBP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TBP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TBP is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: TBP is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TBP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TBP is overvalued based on its PB Ratio (2.8x) compared to the CA Pharmaceuticals industry average (2.5x).
How is Tetra Bio-Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tetra Bio-Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Tetra Bio-Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TBP is currently unprofitable.
Growing Profit Margin: TBP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TBP is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.
Accelerating Growth: Unable to compare TBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: TBP has a negative Return on Equity (-79.22%), as it is currently unprofitable.
How is Tetra Bio-Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: TBP's short term assets (CA$17.8M) exceed its short term liabilities (CA$5.2M).
Long Term Liabilities: TBP's short term assets (CA$17.8M) exceed its long term liabilities (CA$3.0M).
Debt to Equity History and Analysis
Debt Level: TBP's debt to equity ratio (8.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TBP's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TBP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.7% each year
What is Tetra Bio-Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TBP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TBP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TBP's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Guy Chamberland (59 yo)
Dr. Guy Chamberland, M.Sc., Ph D., Master Herbalist, serves as Chief Executive Officer and Chief Regulatory Officer at Tetra Bio-Pharma Inc. since October 15, 2018 and serves as its Director since June 20,...
CEO Compensation Analysis
Compensation vs Market: Guy's total compensation ($USD371.65K) is above average for companies of similar size in the Canadian market ($USD161.55K).
Compensation vs Earnings: Guy's compensation has increased whilst the company is unprofitable.
Experienced Management: TBP's management team is considered experienced (2.1 years average tenure).
Experienced Board: TBP's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.5%.
Tetra Bio-Pharma Inc.'s employee growth, exchange listings and data sources
- Name: Tetra Bio-Pharma Inc.
- Ticker: TBP
- Exchange: TSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$100.417m
- Shares outstanding: 401.67m
- Website: https://www.tetrabiopharma.com
Number of Employees
- Tetra Bio-Pharma Inc.
- 2316 St. Joseph Boulevard
- K1C 1E8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 22:20|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.